What is Edammo?
Edammo operates within the biotechnology sector, focusing on the development of innovative treatments for significant human diseases. Leveraging physics and AI-driven precision engineering, the company's pipeline includes novel drug candidates targeting conditions such as heart attacks, diabetic vision loss, and multidrug-resistant cancers. Edammo's approach aims to redefine drug discovery and enhance the standard of care, with the potential to impact a vast patient population globally.
How much funding has Edammo raised?
Edammo has raised a total of $15K across 1 funding round:
Debt
$15K
Debt (2021): $15K with participation from PPP
Key Investors in Edammo
PPP
Public-Private Partnership
What's next for Edammo?
With the recent injection of moderate growth capital, Edammo is poised for significant expansion and development. This strategic financing is expected to accelerate the advancement of its drug pipeline, potentially leading to breakthroughs in treating complex diseases. The company's focus on physics and AI-driven precision engineering suggests a commitment to cutting-edge research and development, aiming to establish new benchmarks in pharmaceutical innovation and patient care.
See full Edammo company page
